Reading the offer · 6 company examples
FDA Letters About Price and Drug Equivalence Claims
A lower price does not establish an equivalent product
A discount is most persuasive when the reader believes the two offers buy the same thing. These letters include advertising that connects affordability, savings or a price comparison to a brand or ingredient comparison.
The FDA concern is the representation about the medication, not an independent audit of whether the advertised dollars were charged. To compare the economics fairly, separate that representation from the price: identify the actual product, term, refills, consultation fees and cancellation conditions.
The specific company passages below show where the argument joined price and sameness. A letter does not by itself establish that the company stopped operating or that every offer it makes is inaccurate.
An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.
This guide was organized in October 2026. Each company’s source-check date below is kept separately; the guide date does not mean its letter status was checked again.
Dr. Gater’s Weight Loss & Wellness
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted four passages, and the longest is a price pitch rather than an equivalence claim: "While the Brand Ozempic from retail pharmacies is extremely expensive, Dr. Gater has licensed pharmacies that can dispense Brand Ozempic at a much more affordable price. You can purchase Brand Ozempic through our website at a significant cost savings." The other three assert equivalence outright — "Semaglutide,[sic] is the generic version of Ozempic/Wegovy", "Compounded Semiglutide [sic] is the generic equivalent of the brand names and pharmacologically similar to Ozempic & Wegovy", and "Tirzepatide is the active ingredient in Mounjaro…." FDA concluded that "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
This is the one letter here where the money is the point rather than a side effect. Most cited copy claims the compounded drug equals the brand; this site went further and said it could sell you the brand itself, through "licensed pharmacies", at "a significant cost savings" over retail. Those are two very different offers sitting on one page — a compounded product described as "the generic version", and a genuine brand-name product described as cheap — and a shopper moving between them has no way to tell which one a given price belongs to. There is no generic Ozempic; the patents have not expired and FDA has approved no generic semaglutide, so a page that uses the word about a compounded product is not describing a regulatory category that exists. FDA's finding is confined to that copy. It makes no claim about the medication's safety, about the pharmacies involved, or about the clinician's care. The practical takeaway is narrow and useful: when a site offers both a brand and a compounded version, make it say in writing which one your money is buying, at what dose, before you pay. The storefront was password-locked when we checked, so none of that copy is currently readable by a customer.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Dr. Gater’s Weight Loss & Wellness' website] in September 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
“Semaglutide,[sic] is the generic version of Ozempic/Wegovy. The generic version Semiglutide [sic] allows for affordability and accessibility to everyday consumers looking to attain a healthy weight.”
“While the Brand Ozempic from retail pharmacies is extremely expensive, Dr. Gater has licensed pharmacies that can dispense Brand Ozempic at a much more affordable price. You can purchase Brand Ozempic through our website at a significant cost savings. All prescription medications including generic Semiglutide [sic] and brand Ozempic require a telemedicine visit with a medical provider prior [sic] a prescription being sent to our partner pharmacies.”
“Compounded Semiglutide [sic] is the generic equivalent of the brand names and pharmacologically similar to Ozempic & Wegovy.”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
In August 2026 Dr. Gater’s Weight Loss & Wellness' website showed only a password-protected "Coming Soon" page titled "Dr. Gater's Weight Loss & Wellness", reading "Coming Soon — We are working on the full version of our new site and will be back shortly", with a phone number, (706) 816-9255, for additional help. A locked store is not a closure: the practice may still be seeing patients by phone, and the store can be reopened at any time. Recorded as unknown, not ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Fancy Meds
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted six claims — the longest list in the September 2025 wave — and two of them tie sameness directly to price: "Though they contain the same active ingredient as branded Ozempic and Wegovy, compounded versions are much more affordable, so you win!" The agency also cited copy describing compounding as done "in an FDA-monitored, state-licensed pharmacy, using FDA-approved ingredients…." FDA said these claims imply the compounded products are the same as an FDA-approved product when they are not.
What it means for the offer
"So you win!" is the whole argument of the compounded GLP-1 market compressed into three words, and this is the one letter in the wave where FDA quoted it directly. The sentence works by conceding nothing: same ingredient, lower price, therefore pure gain. What the letter points out is that the first half is what makes the second half persuasive, and the first half is the part FDA disputes — the compounded product is not the approved one, so "same" is carrying weight it cannot hold. The separate claim about an "FDA-monitored" pharmacy using "FDA-approved ingredients" does similar work on the supply chain. None of this is a finding about the medication itself. It is a finding about an argument. A lower price is still a lower price; it is just not a free one, and the letter is a reminder to price the difference rather than assume it away.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Fancy Meds' website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
“Same active ingredient as Ozempic and Wegovy”
“Compounding semaglutide involves creating small, customized batches of the medication in an FDA-monitored, state-licensed pharmacy, using FDA-approved ingredients….”
“Though they contain the same active ingredient as branded Ozempic and Wegovy, compounded versions are much more affordable, so you win!”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
Fancy Meds' website returned a live storefront when we checked in August 2026, running a checkout discount code and advertising first-month prices for semaglutide and tirzepatide. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted three claims from FWD's website and made no other finding. The first joins affordability to equivalence in one line — "Manage weight affordably with compounded GLP-1, the same active ingredients as Wegovy, Ozempic, Zepbound & Mounjaro" — alongside "Same active ingredient in Mounjaro and Zepbound" and "Same active ingredient as Ozempic and Wegovy". FDA wrote that compounded drug products are not FDA-approved and that these claims "imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
This is the one letter here where the sentence FDA objected to is the sentence a price shopper actually reads. "Manage weight affordably with compounded GLP-1, the same active ingredients as Wegovy, Ozempic, Zepbound & Mounjaro" is a price argument and a sameness argument welded together: the second half is what makes the first half feel like a bargain rather than a different purchase. FDA did not say the price was wrong or the medicine was unsafe — it said the sameness half overstates what has been approved. Which leaves the comparison you were invited to make, brand price versus this price, resting on a premise a regulator has disputed. That is worth knowing before you treat the gap between the two numbers as pure savings.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [FWD's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
“Manage weight affordably with compounded GLP-1, the same active ingredients as Wegovy, Ozempic, Zepbound & Mounjaro” “Same active ingredient in Mounjaro and Zepbound” “Same active ingredient as Ozempic and Wegovy”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
FWD's website returned a live storefront on 2026-08-09, titled "Compounded GLP-1 Medications Online | FWD", headlined "Get weight loss meds delivered." and carrying published monthly prices, so the site was transacting at that check.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Hello Cake
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited a price comparison on Hello Cake's website reading "While the little blue pill costs $90/dose at some pharmacies, we offer Cake Meds, which has the exact same active ingredients as the branded variety for less," together with copy describing "Cake ED Meds" as compounded medication with "high concentrations of Sildenafil (commonly known as 'Viagra') and Tadalafil (commonly known as 'Cialis')." FDA said the "exact same active ingredients as the branded variety" framing implies the compounded product is the same as an FDA-approved product when it is not.
What it means for the offer
This is the letter to read if you have ever compared a telehealth ED price against a pharmacy price and taken the comparison at face value. Hello Cake's $90-a-dose reference point is not what FDA challenged — the agency said nothing about whether that figure is accurate. What it challenged was the second half of the sentence, the claim that the cheaper product has the exact same active ingredients as the branded one, because a compounded combination of sildenafil and tadalafil has not been through FDA approval the way Viagra and Cialis have. A savings claim and an equivalence claim are two different claims, and a letter like this one is FDA objecting only to the second.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Hello Cake's website] in August 2025 and has observed that your website offers various compounded drug products, including products containing sildenafil and tadalafil.
"While the little blue pill costs $90/dose at some pharmacies, we offer Cake Meds, which has the exact same active ingredients as the branded variety for less."
"Cake ED Meds are compounded medication with high concentrations of Sildenafil (commonly known as 'Viagra') and Tadalafil (commonly known as 'Cialis'). The two ingredients are combined into one unique compounded medication...."
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
Hello Cake's website returned a live retail storefront when we checked in August 2026, with an Rx Care category alongside its lubricants and supplements lines and an active first-order discount offer.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
JulyMD
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted an answer from JulyMD's website that runs the full argument for buying the compounded product instead of the brand: "Yes, Semaglutide is the active ingredient in Ozempic and Wegovy… If you're looking for an affordable alternative, consider trying our compounded Semaglutide. It offers the same effective ingredient as Ozempic and Wegovy, but at a fraction of the price." It also cited "Our Semaglutide injection, featuring the same active ingredient as Wegovy and Ozempic, offers a powerful solution," and concluded the claims imply the compounded product is the same as an FDA-approved product when it is not.
What it means for the offer
Most of the copy FDA quoted across these warning letters is banner text. This is a customer-service answer, and that changes how it should be read: the passage FDA objected to is what the company told someone who had already asked whether the cheap version is the same thing. Its structure is the one every price shopper eventually builds for themselves — same ingredient, therefore same drug, therefore the price difference is the only difference. FDA's position is that the middle step does not hold, because approval attaches to a finished product and not to a molecule. The price gap is real and worth chasing. The claim this page attached to it, that nothing but the price is different, is the part FDA said was not established.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [JulyMD's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.
"Our Semaglutide injection, featuring the same active ingredient as Wegovy and Ozempic, offers a powerful solution."
"Yes, Semaglutide is the active ingredient in Ozempic and Wegovy, a medication commonly used to manage type 2 diabetes and support weight loss. If you're looking for an affordable alternative, consider trying our compounded Semaglutide. It offers the same effective ingredient as Ozempic and Wegovy, but at a fraction of the price."
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
JulyMD's website returned a live storefront when we checked in August 2026, still running a semaglutide weight-loss program alongside a lipotropic injection and an anti-aging line.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Kin Meds
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted the price argument itself: "Hit weight management goals with the same weight loss ingredient as brand-name GLP-1 medications, at a fraction of the cost". The sameness claim and the discount are welded into one sentence, and the second cited phrase, "Same Active Ingredient as common brands", repeats the first half of it. FDA said the claims imply the products "have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not," and separately that the pictured label identifies "Kin Meds" as the compounder when it is not.
What it means for the offer
This is the sentence a pricing site exists to examine, because it does two jobs at once. "The same weight loss ingredient as brand-name GLP-1 medications" establishes equivalence; "at a fraction of the cost" collects the payoff. Remove the first clause and the second is just a low price, which is fine and needs no defending. Keep them together and the low price reads as a pure saving with nothing given up — and that is the inference FDA objected to, because the compounded product has not been through the review the brand-name product has. The letter says nothing about whether the price is fair, whether the medication works, or how the company operates. What it usefully establishes is that "a fraction of the cost" is a comparison between two different kinds of product, so the gap is not all margin. Some of it is the review that one of them has and the other does not.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Kin Meds' website], in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.
“Same Active Ingredient as common brands”
“Hit weight management goals with the same weight loss ingredient as brand-name GLP-1 medications, at a fraction of the cost”
The compounded semaglutide and tirzepatide products displayed on your website identify “Kin Meds” on the pictured label, suggesting Kin Meds is the compounder of those drugs when in fact it is not.
Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Kin Meds' website returned a live storefront when we checked in August 2026, listing branded and personalized GLP-1 options alongside hormone, men's health, skin and sexual-health products and lab biomarkers. We did not review every page on the site.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.